B. Riley Research Analysts Decrease Earnings Estimates for TG Therapeutics, Inc. (NASDAQ:TGTX)

TG Therapeutics, Inc. (NASDAQ:TGTX) – Analysts at B. Riley reduced their FY2026 earnings estimates for shares of TG Therapeutics in a research note issued to investors on Tuesday, August 6th. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will post earnings per share of $1.47 for the year, down from their previous estimate of $1.48. B. Riley has a “Buy” rating and a $34.00 price target on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is ($0.01) per share. B. Riley also issued estimates for TG Therapeutics’ FY2027 earnings at $2.43 EPS and FY2028 earnings at $3.36 EPS.

A number of other analysts have also weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $49.00 target price on shares of TG Therapeutics in a report on Tuesday. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $25.00 price objective on shares of TG Therapeutics in a research report on Thursday, April 18th. The Goldman Sachs Group boosted their target price on TG Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Wednesday. Finally, LADENBURG THALM/SH SH lifted their price target on TG Therapeutics from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, May 2nd. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $31.83.

TG Therapeutics Price Performance

Shares of TGTX traded down $0.12 during midday trading on Thursday, hitting $19.92. 3,379,406 shares of the company traded hands, compared to its average volume of 3,674,650. TG Therapeutics has a one year low of $6.46 and a one year high of $23.12. The firm has a market cap of $3.08 billion, a P/E ratio of 86.61 and a beta of 2.23. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.62 and a quick ratio of 2.84. The stock has a 50-day moving average of $18.74 and a 200-day moving average of $16.64.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.08. The company had revenue of $73.47 million during the quarter, compared to analysts’ expectations of $65.92 million. TG Therapeutics had a return on equity of 31.34% and a net margin of 14.24%. The firm’s quarterly revenue was up 357.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.34) earnings per share.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in TGTX. State of New Jersey Common Pension Fund D purchased a new stake in TG Therapeutics in the second quarter worth $2,022,000. Headlands Technologies LLC purchased a new stake in shares of TG Therapeutics in the 2nd quarter worth about $124,000. Ashton Thomas Private Wealth LLC purchased a new position in TG Therapeutics during the 2nd quarter valued at about $35,000. Strategic Financial Concepts LLC purchased a new stake in TG Therapeutics in the second quarter worth about $530,000. Finally, Los Angeles Capital Management LLC increased its stake in shares of TG Therapeutics by 20.4% during the second quarter. Los Angeles Capital Management LLC now owns 92,277 shares of the biopharmaceutical company’s stock valued at $1,642,000 after purchasing an additional 15,661 shares in the last quarter. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.